BRD2 and ovarian carcinoma: The patient was menopause last year, with pre-surgery serum FSH/E2 levels at 170 mIU/15 pg/mL, and the ROMA (ovarian malignancy risk algorithm) test results for an epithelial ovarian cancer risk showed CA125 at 6.89 U/mL and HE4 at 50.40 pmol, indicating a low risk of postmenopausal epithelial ovarian cancer.